Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Aliskiren reduces portal pressure and intrahepatic resistance in biliary cirrhotic rats.

Hsieh YC, Chan CC, Lee KC, Huang YT, Lee FY, Yang YY, Lin HC.

J Chin Med Assoc. 2012 Oct;75(10):501-8. doi: 10.1016/j.jcma.2012.07.001. Epub 2012 Sep 19.

2.

Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis.

Zhou Q, Hennenberg M, Trebicka J, Jochem K, Leifeld L, Biecker E, Sauerbruch T, Heller J.

Gut. 2006 Sep;55(9):1296-305. Epub 2006 Feb 21.

3.

Aliskiren reduces portal pressure in portal hypertensive rats.

Chang CC, Lee WS, Huang HC, Lee FY, Wang SS, Lin HC, Nong JY, Lee SD.

Eur J Clin Invest. 2012 May;42(5):526-33. doi: 10.1111/j.1365-2362.2011.02611.x. Epub 2011 Oct 24.

PMID:
22023532
4.

Terutroban, a TP-receptor antagonist, reduces portal pressure in cirrhotic rats.

Rosado E, Rodríguez-Vilarrupla A, Gracia-Sancho J, Tripathi D, García-Calderó H, Bosch J, García-Pagán JC.

Hepatology. 2013 Oct;58(4):1424-35. doi: 10.1002/hep.26520. Epub 2013 Aug 7.

PMID:
23703868
5.

Increased sinusoidal resistance is responsible for the basal state and endothelin-induced venoconstriction in perfused cirrhotic rat liver.

Shibamoto T, Kamikado C, Koyama S.

Pflugers Arch. 2008 Jun;456(3):467-77. doi: 10.1007/s00424-007-0437-6. Epub 2008 Jan 5.

PMID:
18193271
6.

Portal pressure responses and angiotensin peptide production in rat liver are determined by relative activity of ACE and ACE2.

Herath CB, Lubel JS, Jia Z, Velkoska E, Casley D, Brown L, Tikellis C, Burrell LM, Angus PW.

Am J Physiol Gastrointest Liver Physiol. 2009 Jul;297(1):G98-G106. doi: 10.1152/ajpgi.00045.2009. Epub 2009 Apr 23.

7.

Administration of a low dose of sildenafil for 1 week decreases intrahepatic resistance in rats with biliary cirrhosis: the role of NO bioavailability.

Lee KC, Yang YY, Huang YT, Lee FY, Hou MC, Lin HC, Lee SD.

Clin Sci (Lond). 2010 Apr 7;119(1):45-55. doi: 10.1042/CS20090601.

PMID:
20132096
8.
9.

Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats.

Laleman W, Van Landeghem L, Van der Elst I, Zeegers M, Fevery J, Nevens F.

Gastroenterology. 2007 Feb;132(2):709-19. Epub 2006 Dec 20.

PMID:
17258737
10.

Nebivolol treatment increases splanchnic blood flow and portal pressure in cirrhotic rats via modulation of nitric oxide signalling.

Reiberger T, Payer BA, Schwabl P, Hayden H, Horvatits T, Jäger B, Hummel T, Mitterhauser M, Trauner M, Fuhrmann V, Angermayr B, Peck-Radosavljevic M; Vienna Hepatic Hemodynamic Lab.

Liver Int. 2013 Apr;33(4):561-8. doi: 10.1111/liv.12101. Epub 2013 Jan 20.

PMID:
23331709
11.

Vasopressin response and shunting modulation in cirrhotic rats by chronic nitric oxide inhibition.

Huang HC, Wang SS, Lee FY, Chang CC, Chang FY, Lin HC, Hou MC, Lee SD.

J Gastroenterol Hepatol. 2008 Jul;23(7 Pt 2):e265-9. Epub 2007 Aug 30.

PMID:
17764528
12.

NCX-1000, a nitric oxide-releasing derivative of ursodeoxycholic acid, ameliorates portal hypertension and lowers norepinephrine-induced intrahepatic resistance in the isolated and perfused rat liver.

Fiorucci S, Antonelli E, Brancaleone V, Sanpaolo L, Orlandi S, Distrutti E, Acuto G, Clerici C, Baldoni M, Del Soldato P, Morelli A.

J Hepatol. 2003 Dec;39(6):932-9.

PMID:
14642608
13.

Tempol administration, a superoxide dismutase mimetic, reduces hepatic vascular resistance and portal pressure in cirrhotic rats.

García-Calderó H, Rodríguez-Vilarrupla A, Gracia-Sancho J, Diví M, Laviña B, Bosch J, García-Pagán JC.

J Hepatol. 2011 Apr;54(4):660-5. doi: 10.1016/j.jhep.2010.07.034. Epub 2010 Sep 25.

PMID:
21159403
14.

Amiloride reduces portal hypertension in rat liver cirrhosis.

Steib CJ, Hennenberg M, Beitinger F, Hartmann AC, Bystron M, De Toni EN, Gerbes AL.

Gut. 2010 Jun;59(6):827-36. doi: 10.1136/gut.2009.197756.

PMID:
20551467
15.

Activation of the MAS receptor by angiotensin-(1-7) in the renin-angiotensin system mediates mesenteric vasodilatation in cirrhosis.

Grace JA, Klein S, Herath CB, Granzow M, Schierwagen R, Masing N, Walther T, Sauerbruch T, Burrell LM, Angus PW, Trebicka J.

Gastroenterology. 2013 Oct;145(4):874-884.e5. doi: 10.1053/j.gastro.2013.06.036. Epub 2013 Jun 22.

PMID:
23796456
16.
17.

Acute haemodynamic effects of losartan in anaesthetized cirrhotic rats.

Heller J, Shiozawa T, Trebicka J, Hennenberg M, Schepke M, Neef M, Sauerbruch T.

Eur J Clin Invest. 2003 Nov;33(11):1006-12.

PMID:
14636305
18.

The direct renin inhibitor aliskiren improves vascular remodelling in transgenic rats harbouring human renin and angiotensinogen genes.

Savoia C, Arrabito E, Parente R, Sada L, Madaro L, Nicoletti C, Zezza L, Alonzo A, Rubattu S, Michelini S, Muller DN, Volpe M.

Clin Sci (Lond). 2013 Aug;125(4):183-9. doi: 10.1042/CS20120395.

PMID:
23438195
19.

HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects.

Klein S, Van Beuge MM, Granzow M, Beljaars L, Schierwagen R, Kilic S, Heidari I, Huss S, Sauerbruch T, Poelstra K, Trebicka J.

J Hepatol. 2012 Dec;57(6):1220-7. doi: 10.1016/j.jhep.2012.07.033. Epub 2012 Aug 6.

PMID:
22878469
20.

Chronic administration of ursodeoxycholic acid decreases portal pressure in rats with biliary cirrhosis.

Yang YY, Huang YT, Lee KC, Lee FY, Lee TY, Hou MC, Lin HC, Lee SD.

Clin Sci (Lond). 2009 Jan;116(1):71-9. doi: 10.1042/CS20080075.

PMID:
18479249

Supplemental Content

Support Center